Movie description of the B horror move Death PhD. Gawdawful movie.
Now this is a movie plot!!! Someone understands grad school.
Movie description of the B horror move Death PhD. Gawdawful movie.
Now this is a movie plot!!! Someone understands grad school.
Great article featuring our work on a new target for lymphoma treatment:
news.med.miami.edu/r01-grant-fo...
This @nytimes.com article is a true public service and illustrates the requirement for high-quality journalism in a free society. To those who care only about a conclusion they want to hold onto, the facts will never matter. To the rest of us, it holds us together.
www.nytimes.com/interactive/...
Catch up on bispecifics with our new review, just published online. @springernature.com
link.springer.com/article/10.1...
Proud to announce online publication. Amazing work by Paola Manara and the whole Schatz lab. And congrats to @aacrjournals.bsky.social for Cancer Research Impact Factor now 16.6!
aacrjournals.org/cancerres/ar...
Miami Cubans get it.
Thousands in Downtown Miami at the Hands-Off protest
After receiving this score yesterday on our R01 at the National Cancer Institute, I can only express my deepest gratitude to the dedicated, hard-working employees at NIH for all they do!
Letter found among my late father's papers from his former post-doc mentor
This Seth approves.
Amazing job by @paolamanara.bsky.social in her PhD defense this morning. Congratulations Dr. Manara, PhD.
Major Congratulations to Schatz lab graduate Caroline Coughlin matching Friday at her No. 1 choice for residency!! @bostonchildrens.bsky.social
Our latest Preprint is up on bioRxiv. Check out exciting new insights on CAR-T resistance in LBCL
doi.org/10.1101/2025...
This will have tragic consequences on medical research. #NIH ban on renewing senior scientists adds to assaults on its in-house research | Science | AAAS www.science.org/content/arti...
Our grad student Olivia Lightfuss' confocal microscopy images displayed in our Office of Graduate Studies. Nice work Liv! @austinnewsam.bsky.social @paolamanara.bsky.social
Tomorrow is #RareDiseaseDay! Did you know that a disease is considered rare when it affects fewer than 1 in 2,000 people? But with 7,000+ rare diseases worldwide, they collectively affect 300M+ people.
Support the ASH Research Awards Fund 🔗 https://bit.ly/3XjCFNr
#hematology #HemeSky #BloodSky
Study section I was scheduled to serve on Thursday and Friday this week, countless hours spent in preparation by me and the rest of the members, canceled today with no explanation given. Why would Putin have ordered this?
With Sylvester Director Stephen Nimer at the 15 Dolphins Cancer Challegne today. 99 miles!
A great way to support Cancer Research in Desperate Times!
dolphinscancerchallenge.com/index.cfm?fu...
We need a new option. Facing a president systematically destroying their country and whose popularity is low and sinking, they have NOTHING to offer. Democratic cowardice got us into this mess, beginning with Obama (the cowardly lion) and moving forward. They know no other way...
Flat Earthers? Don't tempt them
FOIA incoming
DOGE By The Numbers
theonion.com/doge-by...
He's a parody of himself
Thanks to the Cutaneous Lymphoma Foundation for listing our multidisciplinary skin lymphoma clinic. This clinic staffed by me and Georgios Pongas from hematology and Scott Elman from dermatology is an incredible resource for patients affected by these diseases!
www.clfoundation.org/sylvester-co...
BLUETORIAL 6) Read our paper for the fascinating mechanisms of how this all works. Incredible work by our first and many contributing authors over the past several years!
BLUETORIAL 5) We find, however, that a combination of BTK inhibitor, in particular the potent non-covalent compound pirtobrutinib, and venetoclax overcomes resistance. BTK therefore maintains a role in driving resistance even when CBM is activated downstream by BCL10 mutations.
BLUETORIAL 4) BCL10 mutations cluster in BN2/C1 DLBCL cases, which are known to be resistant to BTK inhibitors. We find that BCL10 mutations, in addition to driving BTK inhibitor resistance, drive resistance to multiple other classes of drug, including the BCL2 inhibitor venetoclax
BLUETORIAL 3) Our work now elaborates on the signaling and therapeutic consequences of these activating mechanisms. Detailed gene-expression and mechanistic work shows how mutant-BCL10 mediated CBM activation establishes a cytokine-reinforced positive-feedback loop of lymphomagenesis